AACR IMMUNO-ONCOLOGY (AACR IO)

DISCOVERY AND INNOVATION IN CANCER IMMUNOLOGY: REVOLUTIONIZING TREATMENT THROUGH IMMUNOTHERAPY

February 18–21, 2026 | Los Angeles, CA

AACR American Association for Cancer Research

Current as of February 9, 2026

Oral Presentations
(LB) – Late-Breaking/Clinical Trial Submission

PR001 Inhibition of PSGL-1 overcomes immune suppression and immunotherapy resistance in PDAC. Evelyn Sanchez Hernandez. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

PR002 Spatial and molecular landscape in clear cell renal cell carcinoma bone metastatic patients. Eleonora Dondossola. UT MD Anderson Cancer Center, Houston, TX, United States.

PR003 (LB) Using organoids and tumor infiltrating lymphocytes to elucidate the ”dark matter” of human tumor antigens. Ken-ichi Hanada. Center for Cancer Research, National Cancer Institute, Bethesda, MD, United States.

PR004 Decoding tumor microenvironment and resistance following immune checkpoint inhibition therapy in anaplastic thyroid carcinoma. Kartik Sehgal. Dana-Farber Cancer Institute, Boston, MA, United States.

PR005 A versatile microRNA-based platform for activation-dependent regulation of armored CAR T cell payloads. Nina Barceló-Genestar. IDIBAPS, Barcelona, Spain.

PR006 IL-12 armored anti-macrophage CAR T cells reset and reprogram the tumor microenvironment to control metastatic ovarian and lung tumor growth.. Jaime Mateus-tique. Icahn School of Medicine, New York, NY, United States.

PR007 STING-mediated Myeloid Reprogramming Drives Immunotherapy Response in DNA Repair Mutant Tumors. Robert Samstein. Icahn School of Medicine at Mount Sinai, New York, NY, United States.

PR008 Epithelial alarmins coordinate type 2 immunity in colorectal cancer. Thornton Thompson. University of Washington, Seattle, WA, United States.

PR009 Peripheral Immune Dynamics and Biomarkers of Clinical Response in Patients with Castration-Resistant Prostate Cancer Treated with Combination Immunotherapy. Nicole Toney. National Cancer Institute, Bethesda, MD, United States.

PR010 Impact of polyethylene glycol bowel preparation on the gut microbiome composition and response to immune checkpoint inhibition. Yongjia Hu. Research Center of the Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, QC, Canada.

PR011 Spatial multi-omics identifies a tumor microenvironment signature predictive of immunotherapy response in mucosal melanomas. Suhendan Ekmekcioglu. UT MD Anderson Cancer Center and Cleveland Clinics, Houston, TX, United States.

PR012 Association of different TP53 mutation subtypes with the efficacy of first-line immunotherapy in locally advanced and metastatic lung squamous cell carcinoma. yingyun liang. Shanghai Lung Cancer Center, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, PR China., Shanghai, China.

PR014 Insights into immunotherapy response, irAEs, and pre-treatment conditions impacting patient outcomes from the largest plasma proteomics study of patients receiving immune checkpoint inhibitor therapy. Jerid Robinson. Nomic Bio, Montreal, QC, Canada.

PR015 Regulation of CTLA-4 and PD-1 blockade immunotherapy by distinct subpopulations of CD4 and CD8 tumor-resident memory T cells. Fathia MAMI-CHOUAIB. INSERM-UMR1186, Gustave Roussy, Villejuif, France.

PR016 Genomic and spatial immune biomarkers predictive of chemoimmunotherapy response in triple-negative breast cancer. Mahak Bhargava. University of Alabama at Birmingham, Birmingham, AL, United States.

PR017 Synergizing hypomethylating agents with off-the-shelf CD70-targeted CAR-engineered natural killer T cells for the treatment of acute myeloid leukemia. Yan-Ruide Li. University of California, Los Angeles, Los Angeles, CA, United States.

PR018 Innate lymphoid cell reprogramming reveals immunometabolic and epigenetic signatures following checkpoint blockade in head and neck squamous cell carcinoma (HNSCC). Sujeetha Rajakumar. Johns Hopkins University School of Medicine, Baltimore, MD, United States.

PR019 Tertiary lymphoid structures generate anti-tumor immunity independently of immune responses in secondary lymphoid organs upon STING and lymphotoxin-β receptor activation. Yasuhiro Kikuchi. Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.

PR020 Programmable JAK/STAT signaling drives CAR T cells to enhanced functional states. Wansang Cho. Stanford University, Palo Alto, CA, United States.

PR021 Developing TCR-based precision immunotherapies for EGFR-mutant NSCLC. Yongfeng He. Weill Cornell Medicine, New York, NY, United States.

PR022 p53 promotes anti-tumor immunity of human CD8+ T cells. Joseph Crompton. UCLA, Los Angeles, United States.

PR023 Reprogramming the Tumor Microenvironment Enables T Cell-Mediated Immunotherapies in Pediatric Solid Cancers. Simon Krost. Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

PR024 Postprandial changes to systemic lipid metabolism enhances adaptive immunity. Alok Kumar. University of Pittsburgh, Pittsburgh, PA, United States.

PR025 Histone methyltransferase PRMT5 promotes melanoma immune evasion by repressing T H 1-related gene networks and endogenous retroelements. Simon Milette. Yale University, New Haven, CT, United States.

PR026 TET1 Orchestrates Glucose Metabolism and Counteracts TNBC Aggressiveness under the Oncogenic stress. Hsin-Ling Hsu. National Health Research Institutes, Zhunan, Taiwan.

PR027 The T cell precursor frequency determines the immunogenicity of cancer neoantigens. Tzu-Jiun Kuo. Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

PR028 Leveraging PSGL-1 blockade to elicit responses to anti-PD-1 immunotherapy resistant melanoma. Hannah Hetrick. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States.

PR029 Targeting cancer-intrinsic neddylation overcomes resistance to immune checkpoint blockade therapy in interferon-deficient tumors. Marta Rúbies Bedós. Rudbeck Laboratory, Uppsala University, Uppsala, Sweden.

PR030 (LB) Epigenetic immune reprogramming overcomes PD-1 resistance in metastatic melanoma patients: the phase II NIBIT-ML1 study. Anna Maria Di Giacomo. University of Siena and Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.

PR031 (LB) Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: results from an ongoing Phase I trial. Tim Remus. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.

PR032 (LB) Phase 1 trial of bispecific CART19/20 cells for relapsed or refractory non-hodgkin lymphoma: updated results with over two years median follow up. Sophie Carlson. UCLA, Los Angeles, CA, United States.

PR033 (LB) No effect of the time-of-day infusion of adjuvant pembrolizumab in the outcomes of patients with resectable melanoma in the NCI/SWOG trial S1404. Megan Othus. Fred Hutchinson Cancer Center, Seattle, WA, United States.

PR034 Agonistic CD137 (4-1BB) anchored immunotherapy (ANK-203) elicits potent 4-1BBL signaling in vitro and therapeutic responses against established tumors without systemic toxicity in vivo. Robert Newman. Ankyra Therapeutics, Cambridge, MA, United States.

PR035 Antibody-lectin chimeras for glyco-immune checkpoint blockade. Megan Priestley. Massachusetts Institute of Technology, Cambridge, MA, United States.

PR037 Inflammatory spatial niches distinguished by antigen presentation and interferon response programs explain the high immune response rate of desmoplastic melanoma: Comparison of biopsies from SWOG S1512 and S1616. Daniel Chen. UCLA, Los Angeles, CA, United States.

PR038 Leveraging cDC1 populations for enhanced mRNA cancer vaccination. Ross Ward. Icahn School of Medicine at Mount Sinai, New York, NY, United States.